Glaukos Corporation (NYSE: GKOS) Stock Competitors & Peer Comparison

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, GKOS's ROE is -0.27%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, GKOS is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BSX-PA's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ABT trades at $100.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ABT's P/E ratio is 19.38. In terms of profitability, GKOS's ROE is -0.27%, compared to ABT's ROE of +0.11%. Regarding short-term risk, GKOS is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ABT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, MDT has a market cap of 114.5B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while MDT trades at $88.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas MDT's P/E ratio is 16.18. In terms of profitability, GKOS's ROE is -0.27%, compared to MDT's ROE of +0.11%. Regarding short-term risk, GKOS is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check MDT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SYK has a market cap of 105.6B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SYK trades at $277.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SYK's P/E ratio is 20.57. In terms of profitability, GKOS's ROE is -0.27%, compared to SYK's ROE of +0.16%. Regarding short-term risk, GKOS is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SYK's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BSX has a market cap of 65.6B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BSX trades at $43.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BSX's P/E ratio is 14.23. In terms of profitability, GKOS's ROE is -0.27%, compared to BSX's ROE of +0.15%. Regarding short-term risk, GKOS is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BSX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, EW has a market cap of 50B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while EW trades at $86.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas EW's P/E ratio is 32.16. In terms of profitability, GKOS's ROE is -0.27%, compared to EW's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check EW's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while DXCM trades at $86.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas DXCM's P/E ratio is 33.99. In terms of profitability, GKOS's ROE is -0.27%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, GKOS is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check DXCM's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, GEHC has a market cap of 30.2B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while GEHC trades at $66.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas GEHC's P/E ratio is 14.64. In terms of profitability, GKOS's ROE is -0.27%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, GKOS is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check GEHC's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, PHG has a market cap of 24.5B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while PHG trades at $24.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas PHG's P/E ratio is 14.35. In terms of profitability, GKOS's ROE is -0.27%, compared to PHG's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check PHG's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ZBH trades at $91.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ZBH's P/E ratio is 10.80. In terms of profitability, GKOS's ROE is -0.27%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, GKOS is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ZBH's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ABMD's P/E ratio is 65.36. In terms of profitability, GKOS's ROE is -0.27%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ABMD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while PEN trades at $318.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas PEN's P/E ratio is 83.31. In terms of profitability, GKOS's ROE is -0.27%, compared to PEN's ROE of +0.11%. Regarding short-term risk, GKOS is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check PEN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SWAV's P/E ratio is 78.76. In terms of profitability, GKOS's ROE is -0.27%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, GKOS is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SWAV's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SNN has a market cap of 11.4B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SNN trades at $26.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SNN's P/E ratio is 18.28. In terms of profitability, GKOS's ROE is -0.27%, compared to SNN's ROE of +0.12%. Regarding short-term risk, GKOS is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SNN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BIO-B trades at $385.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, GKOS's ROE is -0.27%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, GKOS is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BIO-B's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ALGN has a market cap of 10.4B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ALGN trades at $144.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ALGN's P/E ratio is 13.22. In terms of profitability, GKOS's ROE is -0.27%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ALGN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BIO trades at $379.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BIO's P/E ratio is 40.70. In terms of profitability, GKOS's ROE is -0.27%, compared to BIO's ROE of +0.03%. Regarding short-term risk, GKOS is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BIO's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while GMED trades at $74.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas GMED's P/E ratio is 16.84. In terms of profitability, GKOS's ROE is -0.27%, compared to GMED's ROE of +0.12%. Regarding short-term risk, GKOS is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check GMED's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BRKR has a market cap of 9.6B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BRKR trades at $64.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BRKR's P/E ratio is 31.80. In terms of profitability, GKOS's ROE is -0.27%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, GKOS is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BRKR's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas MASI's P/E ratio is 44.43. In terms of profitability, GKOS's ROE is -0.27%, compared to MASI's ROE of +0.09%. Regarding short-term risk, GKOS is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check MASI's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BRKRP trades at $474.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BRKRP's P/E ratio is 251.76. In terms of profitability, GKOS's ROE is -0.27%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, GKOS is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BRKRP's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while PODD trades at $132.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas PODD's P/E ratio is 22.68. In terms of profitability, GKOS's ROE is -0.27%, compared to PODD's ROE of +0.27%. Regarding short-term risk, GKOS is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check PODD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while HAE trades at $106.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas HAE's P/E ratio is 21.13. In terms of profitability, GKOS's ROE is -0.27%, compared to HAE's ROE of +0.11%. Regarding short-term risk, GKOS is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check HAE's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas NARI's P/E ratio is -59.24. In terms of profitability, GKOS's ROE is -0.27%, compared to NARI's ROE of -0.00%. Regarding short-term risk, GKOS is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check NARI's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ITGR trades at $126.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ITGR's P/E ratio is 19.90. In terms of profitability, GKOS's ROE is -0.27%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, GKOS is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ITGR's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while LIVN trades at $76.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas LIVN's P/E ratio is 18.34. In terms of profitability, GKOS's ROE is -0.27%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, GKOS is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check LIVN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while IRTC trades at $114.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas IRTC's P/E ratio is -261.86. In terms of profitability, GKOS's ROE is -0.27%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, GKOS is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check IRTC's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas AXNX's P/E ratio is -709.80. In terms of profitability, GKOS's ROE is -0.27%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, GKOS is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AXNX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while NEOG trades at $13.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas NEOG's P/E ratio is 49.00. In terms of profitability, GKOS's ROE is -0.27%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, GKOS is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check NEOG's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while TMDX trades at $82.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas TMDX's P/E ratio is 41.99. In terms of profitability, GKOS's ROE is -0.27%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, GKOS is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check TMDX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BFLY trades at $9.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BFLY's P/E ratio is -38.10. In terms of profitability, GKOS's ROE is -0.27%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, GKOS is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BFLY's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while AXGN trades at $43.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas AXGN's P/E ratio is 114.11. In terms of profitability, GKOS's ROE is -0.27%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, GKOS is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AXGN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while UFPT trades at $300.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas UFPT's P/E ratio is 30.56. In terms of profitability, GKOS's ROE is -0.27%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, GKOS is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check UFPT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas NUVA's P/E ratio is 75.00. In terms of profitability, GKOS's ROE is -0.27%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, GKOS is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check NUVA's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while INSP trades at $70.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas INSP's P/E ratio is 30.84. In terms of profitability, GKOS's ROE is -0.27%, compared to INSP's ROE of +0.18%. Regarding short-term risk, GKOS is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check INSP's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ESTA trades at $65.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ESTA's P/E ratio is -51.86. In terms of profitability, GKOS's ROE is -0.27%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, GKOS is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ESTA's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while NVCR trades at $15.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas NVCR's P/E ratio is -12.18. In terms of profitability, GKOS's ROE is -0.27%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, GKOS is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check NVCR's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ATEC trades at $10.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ATEC's P/E ratio is -167.50. In terms of profitability, GKOS's ROE is -0.27%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, GKOS is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ATEC's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CNMD trades at $46.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CNMD's P/E ratio is 10.20. In terms of profitability, GKOS's ROE is -0.27%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, GKOS is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CNMD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas HSKA's P/E ratio is -62.49. In terms of profitability, GKOS's ROE is -0.27%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, GKOS is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check HSKA's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while IART trades at $16.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas IART's P/E ratio is 6.89. In terms of profitability, GKOS's ROE is -0.27%, compared to IART's ROE of -0.01%. Regarding short-term risk, GKOS is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check IART's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas AVNS's P/E ratio is 27.77. In terms of profitability, GKOS's ROE is -0.27%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, GKOS is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AVNS's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while TNDM trades at $16.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas TNDM's P/E ratio is -17.66. In terms of profitability, GKOS's ROE is -0.27%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, GKOS is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check TNDM's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SILK's P/E ratio is -18.96. In terms of profitability, GKOS's ROE is -0.27%, compared to SILK's ROE of -0.35%. Regarding short-term risk, GKOS is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SILK's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while AORT trades at $22.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas AORT's P/E ratio is 38.23. In terms of profitability, GKOS's ROE is -0.27%, compared to AORT's ROE of -0.01%. Regarding short-term risk, GKOS is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AORT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while IRMD trades at $86.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas IRMD's P/E ratio is 43.55. In terms of profitability, GKOS's ROE is -0.27%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, GKOS is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check IRMD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas FNA's P/E ratio is -19.83. In terms of profitability, GKOS's ROE is -0.27%, compared to FNA's ROE of -0.35%. Regarding short-term risk, GKOS is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check FNA's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ENOV trades at $18.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ENOV's P/E ratio is 5.20. In terms of profitability, GKOS's ROE is -0.27%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, GKOS is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ENOV's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, PRCT has a market cap of 981.9M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while PRCT trades at $16.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas PRCT's P/E ratio is -8.89. In terms of profitability, GKOS's ROE is -0.27%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, GKOS is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check PRCT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, LMRI has a market cap of 974.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while LMRI trades at $10.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas LMRI's P/E ratio is -19.74. In terms of profitability, GKOS's ROE is -0.27%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, GKOS is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check LMRI's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BVS has a market cap of 949.8M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BVS trades at $13.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BVS's P/E ratio is 18.45. In terms of profitability, GKOS's ROE is -0.27%, compared to BVS's ROE of +0.28%. Regarding short-term risk, GKOS is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BVS's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CBLL has a market cap of 930M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CBLL trades at $24.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CBLL's P/E ratio is -13.93. In terms of profitability, GKOS's ROE is -0.27%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, GKOS is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CBLL's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BBNX has a market cap of 923.2M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BBNX trades at $20.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BBNX's P/E ratio is -12.44. In terms of profitability, GKOS's ROE is -0.27%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, GKOS is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BBNX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CSII's P/E ratio is -20.83. In terms of profitability, GKOS's ROE is -0.27%, compared to CSII's ROE of -0.14%. Regarding short-term risk, GKOS is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CSII's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SIBN has a market cap of 832M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SIBN trades at $18.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SIBN's P/E ratio is -55.18. In terms of profitability, GKOS's ROE is -0.27%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, GKOS is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SIBN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, INMD has a market cap of 816.5M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while INMD trades at $14.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas INMD's P/E ratio is 9.86. In terms of profitability, GKOS's ROE is -0.27%, compared to INMD's ROE of +0.12%. Regarding short-term risk, GKOS is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check INMD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, VREX has a market cap of 777.2M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while VREX trades at $18.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas VREX's P/E ratio is 19.43. In terms of profitability, GKOS's ROE is -0.27%, compared to VREX's ROE of +0.05%. Regarding short-term risk, GKOS is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check VREX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, AHCO has a market cap of 768.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while AHCO trades at $5.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas AHCO's P/E ratio is 11.53. In terms of profitability, GKOS's ROE is -0.27%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, GKOS is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AHCO's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, AVR has a market cap of 752.6M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while AVR trades at $7.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas AVR's P/E ratio is -3.99. In terms of profitability, GKOS's ROE is -0.27%, compared to AVR's ROE of -0.78%. Regarding short-term risk, GKOS is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AVR's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CTKB has a market cap of 741.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CTKB trades at $5.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CTKB's P/E ratio is -30.41. In terms of profitability, GKOS's ROE is -0.27%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, GKOS is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CTKB's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SRDX's P/E ratio is -34.66. In terms of profitability, GKOS's ROE is -0.27%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, GKOS is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SRDX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, KIDS has a market cap of 580M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while KIDS trades at $22.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas KIDS's P/E ratio is -19.14. In terms of profitability, GKOS's ROE is -0.27%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, GKOS is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check KIDS's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas APEN's P/E ratio is -9.43. In terms of profitability, GKOS's ROE is -0.27%, compared to APEN's ROE of -0.85%. Regarding short-term risk, GKOS is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check APEN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SSII trades at $2.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SSII's P/E ratio is -48.17. In terms of profitability, GKOS's ROE is -0.27%, compared to SSII's ROE of -0.27%. Regarding short-term risk, GKOS is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SSII's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, DCTH has a market cap of 545.8M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while DCTH trades at $15.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas DCTH's P/E ratio is 1581.00. In terms of profitability, GKOS's ROE is -0.27%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, GKOS is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check DCTH's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, GKOS's ROE is -0.27%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, GKOS is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ZIMV's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, PACB has a market cap of 531.1M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while PACB trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas PACB's P/E ratio is -4.17. In terms of profitability, GKOS's ROE is -0.27%, compared to PACB's ROE of -49.62%. Regarding short-term risk, GKOS is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check PACB's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, TCMD has a market cap of 514.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while TCMD trades at $22.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas TCMD's P/E ratio is 21.13. In terms of profitability, GKOS's ROE is -0.27%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, GKOS is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check TCMD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SGHT has a market cap of 504.4M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SGHT trades at $9.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SGHT's P/E ratio is -16.55. In terms of profitability, GKOS's ROE is -0.27%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, GKOS is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SGHT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CERS has a market cap of 493.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CERS trades at $2.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CERS's P/E ratio is -81.40. In terms of profitability, GKOS's ROE is -0.27%, compared to CERS's ROE of -0.10%. Regarding short-term risk, GKOS is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CERS's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, NPCE has a market cap of 482.4M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while NPCE trades at $14.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas NPCE's P/E ratio is -24.82. In terms of profitability, GKOS's ROE is -0.27%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, GKOS is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check NPCE's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CLPT has a market cap of 459.1M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CLPT trades at $11.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CLPT's P/E ratio is -12.97. In terms of profitability, GKOS's ROE is -0.27%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, GKOS is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CLPT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SENS has a market cap of 411.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SENS trades at $9.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SENS's P/E ratio is -4.41. In terms of profitability, GKOS's ROE is -0.27%, compared to SENS's ROE of -1.66%. Regarding short-term risk, GKOS is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SENS's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, OFIX has a market cap of 397.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while OFIX trades at $9.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas OFIX's P/E ratio is -6.41. In terms of profitability, GKOS's ROE is -0.27%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, GKOS is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check OFIX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CV has a market cap of 345.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CV trades at $6.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CV's P/E ratio is -10.98. In terms of profitability, GKOS's ROE is -0.27%, compared to CV's ROE of -1.78%. Regarding short-term risk, GKOS is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CV's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas SMLR's P/E ratio is 3.92. In terms of profitability, GKOS's ROE is -0.27%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, GKOS is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SMLR's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, TMCI has a market cap of 290.6M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while TMCI trades at $4.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas TMCI's P/E ratio is -4.77. In terms of profitability, GKOS's ROE is -0.27%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, GKOS is more volatile compared to TMCI. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check TMCI's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, RCEL has a market cap of 289.9M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while RCEL trades at $11.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas RCEL's P/E ratio is -8.10. In terms of profitability, GKOS's ROE is -0.27%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, GKOS is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check RCEL's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, CATX has a market cap of 286.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while CATX trades at $2.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas CATX's P/E ratio is -1.89. In terms of profitability, GKOS's ROE is -0.27%, compared to CATX's ROE of -0.42%. Regarding short-term risk, GKOS is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CATX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, TLSI has a market cap of 270.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while TLSI trades at $4.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas TLSI's P/E ratio is -2.61. In terms of profitability, GKOS's ROE is -0.27%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, GKOS is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check TLSI's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, INFU has a market cap of 259.4M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while INFU trades at $12.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas INFU's P/E ratio is 31.35. In terms of profitability, GKOS's ROE is -0.27%, compared to INFU's ROE of +0.15%. Regarding short-term risk, GKOS is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check INFU's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas MGRM's P/E ratio is -12.00. In terms of profitability, GKOS's ROE is -0.27%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, GKOS is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check MGRM's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ELMD has a market cap of 233.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ELMD trades at $27.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ELMD's P/E ratio is 21.51. In terms of profitability, GKOS's ROE is -0.27%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, GKOS is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ELMD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas NVRO's P/E ratio is -1.91. In terms of profitability, GKOS's ROE is -0.27%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, GKOS is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check NVRO's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, PROF has a market cap of 215.1M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while PROF trades at $5.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas PROF's P/E ratio is -6.04. In terms of profitability, GKOS's ROE is -0.27%, compared to PROF's ROE of -0.56%. Regarding short-term risk, GKOS is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check PROF's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, RXST has a market cap of 193.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while RXST trades at $4.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas RXST's P/E ratio is -4.13. In terms of profitability, GKOS's ROE is -0.27%, compared to RXST's ROE of -0.17%. Regarding short-term risk, GKOS is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check RXST's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas BSGM's P/E ratio is -5.81. In terms of profitability, GKOS's ROE is -0.27%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, GKOS is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BSGM's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas MDGS's P/E ratio is -0.27. In terms of profitability, GKOS's ROE is -0.27%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, GKOS is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check MDGS's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, STIM has a market cap of 177.8M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while STIM trades at $2.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas STIM's P/E ratio is -5.81. In terms of profitability, GKOS's ROE is -0.27%, compared to STIM's ROE of -1.51%. Regarding short-term risk, GKOS is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check STIM's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, FOCL has a market cap of 169.8M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while FOCL trades at $4.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas FOCL's P/E ratio is -4.38. In terms of profitability, GKOS's ROE is -0.27%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, GKOS is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check FOCL's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, QTRX has a market cap of 165.8M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while QTRX trades at $3.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas QTRX's P/E ratio is -1.39. In terms of profitability, GKOS's ROE is -0.27%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, GKOS is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check QTRX's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas QIPT's P/E ratio is -15.87. In terms of profitability, GKOS's ROE is -0.27%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, GKOS is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check QIPT's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, QSI has a market cap of 157.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while QSI trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas QSI's P/E ratio is -1.73. In terms of profitability, GKOS's ROE is -0.27%, compared to QSI's ROE of -0.47%. Regarding short-term risk, GKOS is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check QSI's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, LUCD has a market cap of 153.7M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while LUCD trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas LUCD's P/E ratio is -2.18. In terms of profitability, GKOS's ROE is -0.27%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, GKOS is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check LUCD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, INGN has a market cap of 147.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while INGN trades at $5.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas INGN's P/E ratio is -5.98. In terms of profitability, GKOS's ROE is -0.27%, compared to INGN's ROE of -0.13%. Regarding short-term risk, GKOS is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check INGN's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ICAD's P/E ratio is -20.37. In terms of profitability, GKOS's ROE is -0.27%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, GKOS is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ICAD's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ECOR has a market cap of 99.4M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ECOR trades at $11.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ECOR's P/E ratio is -6.57. In terms of profitability, GKOS's ROE is -0.27%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, GKOS is more volatile compared to ECOR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ECOR's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas HJLI's P/E ratio is N/A. In terms of profitability, GKOS's ROE is -0.27%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, GKOS is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check HJLI's competition here

Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GKOS stands at 9.3B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, GKOS is priced at $157.07 on the NYSE, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GKOS currently has a P/E ratio of -184.31, whereas ASXC's P/E ratio is -1.12. In terms of profitability, GKOS's ROE is -0.27%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, GKOS is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ASXC's competition here